- Home
- POAI vs HOOK Comparison
POAI vs HOOK Comparison
Compare POAI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- HOOK
- Stock Information
- Founded
- POAI 2002
- HOOK 2011
- Country
- POAI United States
- HOOK United States
- Employees
- POAI N/A
- HOOK N/A
- Industry
- POAI Industrial Specialties
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- HOOK Health Care
- Exchange
- POAI Nasdaq
- HOOK Nasdaq
- Market Cap
- POAI 8.9M
- HOOK 9.3M
- IPO Year
- POAI N/A
- HOOK 2019
- Fundamental
- Price
- POAI $0.89
- HOOK $1.25
- Analyst Decision
- POAI Hold
- HOOK Buy
- Analyst Count
- POAI 1
- HOOK 4
- Target Price
- POAI N/A
- HOOK $10.67
- AVG Volume (30 Days)
- POAI 93.9K
- HOOK 62.9K
- Earning Date
- POAI 08-12-2025
- HOOK 08-07-2025
- Dividend Yield
- POAI N/A
- HOOK N/A
- EPS Growth
- POAI N/A
- HOOK N/A
- EPS
- POAI N/A
- HOOK N/A
- Revenue
- POAI $1,729,269.00
- HOOK $9,351,000.00
- Revenue This Year
- POAI $486.27
- HOOK N/A
- Revenue Next Year
- POAI $65.50
- HOOK N/A
- P/E Ratio
- POAI N/A
- HOOK N/A
- Revenue Growth
- POAI 24.17
- HOOK N/A
- 52 Week Low
- POAI $0.55
- HOOK $0.72
- 52 Week High
- POAI $3.06
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- POAI 38.00
- HOOK 38.94
- Support Level
- POAI $0.85
- HOOK $1.23
- Resistance Level
- POAI $0.91
- HOOK $1.30
- Average True Range (ATR)
- POAI 0.06
- HOOK 0.06
- MACD
- POAI -0.00
- HOOK -0.03
- Stochastic Oscillator
- POAI 4.12
- HOOK 5.97
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.